Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting Phase 2 Trials for Eculizumab (DB01257)

Also known as: Atypical Hemolytic Uremic Syndrome

IndicationStatusPhase
DBCOND0061539 (Atypical Hemolytic Uremic Syndrome (aHUS))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03518203Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsTreatment